Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
- Conditions
- HIV InfectionsHepatitis B
- Interventions
Once-Daily Drug Regimen for HIV-Infected Patients
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00001968
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus I
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 240
- Registration Number
- NCT00046176
- Locations
- 🇵🇷
GSK Investigational Site, Rio Piedras, Puerto Rico
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 166
- Registration Number
- NCT00044577
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: atazanavir/ritonavir dosage #1Drug: tipranavir/ritonavirDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #3Drug: levoflaxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Increasing HAART-Induced Immune Restoration With Cyclosporine
- Conditions
- HIV Infections
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2015-03-09
- Target Recruit Count
- 40
- Registration Number
- NCT00031070
- Locations
- 🇺🇸
Univ of Texas, Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Washington Univ (St. Louis), St. Louis, Missouri, United States
🇺🇸University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
- Conditions
- HIV InfectionsLipodystrophyWasting Disease
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 150
- Registration Number
- NCT00028314
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Washington U CRS, St. Louis, Missouri, United States
🇺🇸Univ. of Texas Medical Branch, ACTU, Galveston, Texas, United States
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00000872
- Locations
- 🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002391
- Locations
- 🇺🇸
Children's Hosp Los Angeles, Los Angeles, California, United States
🇺🇸Children's Diagnostic Treatment Ctr, Fort Lauderdale, Florida, United States
🇺🇸UMDNJ / Division of Allergy Immunology & Infectious Diseases, Newark, New Jersey, United States
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-05-15
- Target Recruit Count
- 25
- Registration Number
- NCT00006617
- Locations
- 🇺🇸
Aaron Diamond AIDS Res Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.